NCT02084940 - Long Acting GnRH Antagonist in PCOS Women Undergoing IVF | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

February 28, 2015

Conditions

Polycystic Ovarian SyndromeOvarian Hyperstimulation SyndromeInvitro Fertilization

Interventions

DRUG

GnRH antagonist depot Degarelix

Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering

Trial Locations (1)

00197

RECRUITING

Bioroma, Rome